Recommended as first-line treatment per the RRP Foundation consensus statement.1,2

Intended for US healthcare professionals only.

PAPZIMEOS support & resources

Help your patients get started on PAPZIMEOS

Papzimeos SUPPORT

Precigen is committed to providing support to patients and healthcare professionals for PAPZIMEOS. As part of this commitment, Papzimeos SUPPORT can provide information to help you understand the administrative aspects of the access and reimbursement process.

Find information on:

  • Order supportHelp coordinating ordering and delivery of PAPZIMEOS via specialty pharmacy services
  • Understanding coverageHelp understanding the insurance process and what information a patient’s health plan may need
  • Insurance navigationSupport during the process of determining a patient’s insurance benefits for PAPZIMEOS and eligibility for affordability programs
  • Financial assistanceInformation about available resources that may help to reduce or eliminate a patient’s out-of-pocket costs
  • Treatment educationSupport throughout the treatment process, including education about PAPZIMEOS

This information will feature an overview of the access process, including:

  • Benefits investigation
  • Medical Exceptions and Sample Letter of Medical Necessity
  • Prior authorization (PA)
  • Appeals

Commercial and government insurers all have different coverage and payment policies for medications and services. Check directly with the patient’s insurer(s) to verify specific requirements for PAPZIMEOS.

Papzimeos SUPPORT can help support your patients and care team at any site of care throughout the access process. Download the enrollment form below.

For questions or support, call (866) 827-8180, Monday to Friday, 8 AM to 8 PM ET.

PAPZIMEOS resources

Papzimeos SUPPORT

Explore how Precigen can support your patients and care team. For questions or to get started, call (866) 827-8180(866) 827-8180.

Papzimeos SUPPORT Brochure

Papzimeos SUPPORT Enrollment Form

Enroll your patients in Papzimeos SUPPORT for support throughout the access process.

Papzimeos SUPPORT Enrollment Form

Billing & Coding

Submit claims with billing and coding resources for PAPZIMEOS.

Billing & Coding Guide

Distribution & Product Ordering

Follow this step-by-step process for ordering and receiving PAPZIMEOS shipments.

Distribution & Ordering Guide

Dosing & Administration

Learn how to properly prepare and inject PAPZIMEOS.

Dosing & Administration Guide

Efficacy & Safety

Dive into clinical studies and data to better understand how PAPZIMEOS may help your patients.

PAPZIMEOS Brochure

Navigating Access & Getting Started

Follow this guide to navigate the access and reimbursement process for PAPZIMEOS.

Navigating Access & Getting Started Guide

PAPZIMEOS for Patients

Help your patients learn more about PAPZIMEOS.

Patient Brochure

Sign up & connect

Learn more about PAPZIMEOS or connect with a PAPZIMEOS representative.

Register today

INDICATION

PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.

Important Safety Information

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.

Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.

ADVERSE REACTIONS

The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no available data with PAPZIMEOS in pregnant women.

Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.

Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.

To report SUSPECTED ADVERSE REACTIONS, contact Precigen, Inc. at 1‑855‑PGE‑NRRP (1‑855‑743‑6777) 1‑855‑PGE‑NRRP (1‑855‑743‑6777) or medinfo@precigen.com or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.

Important Safety Information

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.

Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.

ADVERSE REACTIONS

The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no available data with PAPZIMEOS in pregnant women.

Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.

Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.

To report SUSPECTED ADVERSE REACTIONS, contact Precigen, Inc. at 1‑855‑PGE‑NRRP (1‑855‑743‑6777) 1‑855‑PGE‑NRRP (1‑855‑743‑6777) or medinfo@precigen.com or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.

Important Safety Information

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.

Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.

ADVERSE REACTIONS

The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no available data with PAPZIMEOS in pregnant women.

Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.

Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.

To report SUSPECTED ADVERSE REACTIONS, contact Precigen, Inc. at 1‑855‑PGE‑NRRP (1‑855‑743‑6777) 1‑855‑PGE‑NRRP (1‑855‑743‑6777) or medinfo@precigen.com or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

References: 1. PAPZIMEOS. Package insert. Precigen, Inc; 2025. 2. Best SR, Friedman AD, Rosen CA, et al. Recurrent Respiratory Papillomatosis Foundation position statement on the management of adults with RRP. Laryngoscope. Published online January 16, 2026. doi:10.1002/lary.70379